Use of Granulocyte Colony-Stimulating Factor After High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation
| Autor: | King Rs, Isadore Brodsky, Meglathery Sb, Ener Ra, David Topolsky, Kahn Sb, Pamela Crilley, Michael Styler, Cuhaci B |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Neutropenia Transplantation Conditioning medicine.medical_treatment Breast Neoplasms Hematopoietic stem cell transplantation Granulocyte Drug Administration Schedule Leukocyte Count Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Humans Medicine Retrospective Studies Body surface area Chemotherapy Dose-Response Relationship Drug business.industry Lymphoma Non-Hodgkin Hematopoietic Stem Cell Transplantation Length of Stay Middle Aged medicine.disease Combined Modality Therapy Granulocyte colony-stimulating factor Surgery medicine.anatomical_structure Oncology Case-Control Studies Anesthesia Absolute neutrophil count Female business |
| Zdroj: | American Journal of Clinical Oncology: Cancer Clinical Trials. 24:19-25 |
| ISSN: | 0277-3732 |
| Popis: | Administration of granulocyte colony-stimulating factor to patients undergoing high-dose chemotherapy and autologous peripheral blood stem cell transplantation accelerates neutrophil recovery and decreases hospitalization time. The optimal timing for granulocyte colony-stimulating factor infusion remains unknown. In this retrospective, case-controlled, two-armed study, we reviewed our experience at Hahnemann University Hospital to determine whether initiating granulocyte colony-stimulating factor infusions on posttransplant day 0 versus day 8 affects neutrophil recovery time, posttransplant discharge date, total hospital days after high-dose chemotherapy, and autologous peripheral blood stem cell transplantation. All patients hospitalized between 1994 and 1998 at Hahnemann University Hospital, Bone Marrow Transplantation Unit with breast cancer or non-Hodgkin's lymphoma, who underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation and received granulocyte colony-stimulating factor either on posttransplant day 0 (16 patients) or day 8 (16 patients). The day 0 and day 8 groups had no statistically significant differences in age, sex, weight, height, body surface area, disease characteristics, pretransplant harvesting or conditioning regimens, or transplant CD34+ cell counts. Our main outcome measure was the mean time to reach absolute neutrophil count greater than or equal to 0.5 x 10(9)/l, the number of hospital days after transplant, and the total hospital days. The mean days to neutrophil recovery (10.56 versus 9.68, p = 0.48), posttransplant hospital days (13.62 versus 12.81, p = 0.39), and total hospital days (20.25 versus 20.25, p = 1.00) were not significantly different between day 8 and day 0 groups, respectively. No significant effects on neutrophil recovery time, posttransplant hospital days, or total hospital days were observed with the initial granulocyte colony-stimulating factor infusion on day 0 versus day 8 after transplant. Delayed administration may allow substantial cost savings (US$200 x 8 approximately equal to US $1,600 per patient) without affecting clinical outcome. More studies are needed to determine whether greater delay is feasible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|